On December 15th, Shanghai Pharmaceutical Holdings and Sanofi China announced the official signing of a strategic cooperation agreement to engage in extensive and in-depth cooperation across all channels and across the country in key disease areas, building an end-to-end value chain system from import, distribution to terminal sales. Both parties will maximize drug accessibility through this win-win cooperation and business model, allowing Sanofi's high-quality products to benefit more Chinese people and contribute to the sustainable development of China's local medical and health ecosystem.
Sanofi Greater China President Shi Wang stated that Shanghai Pharmaceutical Group Co., Ltd. is a leading pharmaceutical operating enterprise in China. He believes that through this strong alliance, combined with the core advantages of the two companies, high-quality drugs can be brought to more Chinese patients. Establishing a pharmaceutical innovation business model with local partners is an important part of Sanofi's China innovation development strategy. Sanofi will accelerate the pace of innovation and research and development, expand the depth and breadth of innovation cooperation, enhance the height of innovation strategy, and achieve a dual focus on innovative product pipelines and innovative business models, so that more innovative, high-quality, and accessible original research drugs and vaccines can benefit the vast Chinese people and make continuous contributions to the Healthy China 2030 Strategy.
Li Yongzhong, Executive Director and CEO of Shanghai Pharmaceutical, stated that this cooperation is one of the largest, widest, and deepest strategic collaborations between pharmaceutical industry and commerce in recent years. Both sides have joined hands to jointly build a new strategic model, greatly improving the efficiency of the pharmaceutical industry chain and promoting deep integration of innovation in the pharmaceutical industry chain. Currently, the fundamental conditions of China's healthcare system are undergoing significant changes, and there is an urgent need for a new market model to achieve a balance and synergy between efficiency and innovation, better serving the Healthy China strategy. This industrial chain cooperation has achieved a perfect combination of local circulation enterprise commercial efficiency and multinational pharmaceutical enterprise innovation advantages, promoting the cross integration of industrial chain innovation chains through the construction of a new ecosystem, and pushing more valuable drugs to the market and benefiting the people in a more efficient way.
It is understood that this cooperation is a comprehensive upgrade of the long-term cooperation between Shanghai Pharmaceutical Holdings and Sanofi China, and has extremely high strategic significance. Both sides will engage in extensive cooperation across all channels and nationwide in key disease areas, including but not limited to cardiovascular diseases, central nervous system diseases, tumors, etc., focusing on multiple high-quality Sanofi products. Through strong partnerships with partners such as Sanofi China, Shanghai Pharmaceutical Holdings aims to continuously strengthen the national omnichannel integrated marketing service system and is committed to building the top brand in China's pharmaceutical commercial marketing.
As a national technology-based health service enterprise, Shanghai Pharmaceutical Group Co., Ltd. always adheres to compliance as the first principle, and takes branding, systematization, and specialization as the organizational construction direction. It continuously iterates and upgrades the "integrated general contracting" model, deeply cultivates the pharmaceutical commercial service field with full channel and full terminal coverage, and promotes the capacity building of various links in the pharmaceutical supply chain through platformization. It has basically formed the core advantages of professional leadership, national layout, and brand management, Shaped a comprehensive strength of high quality, high level, and high efficiency. The deepening of cooperation with Sanofi China this time is a vivid practice of the corporate culture concept of "service is pride" of Shanghai Pharmaceutical Group Co., Ltd. It is an important measure to continuously promote the innovation and breakthrough of supply chain models, and it is also the best proof of the joint growth of Shanghai Pharmaceutical Group Co., Ltd. and the biopharmaceutical industry in terms of high-quality development.